Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Icotrokinra maintains high-impact site psoriasis clearance through 2 years in ICONIC-TOTAL

2 October 2026 · By · Wire by Fusion42

Published

2 October 2026

Topic

opportunities

◆ Sectors

Health: Medtech

◆ Geography

United States

◆ Source

Read at contemporarypediatrics.com →

◆ Verified

Fusion42 · 2 October 2026 · Fusion42 review

Icotrokinra, an oral IL-23 receptor blocker, maintained effective clearance of high-impact site psoriasis for scalp, genital, and hand/foot areas through 2 years in the phase 3 ICONIC-TOTAL trial with no new safety concerns reported.

This Wire brief sits within Fusion42's coverage of Health: Medtech.

◆ ◆ The Wire takeaway

You can position your medtech product as a durable systemic psoriasis treatment by highlighting sustained efficacy in sites that resist topical therapies. This long-term data strengthens oral therapies as a competitive alternative to injections.

◆ Coverage

1 source · 2 Oct 2026

◆ Related on Wire

◆ Topics

Health: Medtechpsoriasisoral-biologicclinical-trialdermatologyIL23-inhibitor